COVID-19 Antigen
Rapid Test (Professional)
High-sensitivity lateral flow chromatographic immunoassay for the rapid, qualitative identification of SARS-CoV-2 nucleocapsid (N) antigen directly from anterior nasal or nasopharyngeal swabs. Delivers definitive visual clinical results in 15 minutes to facilitate immediate infection control and clinical triaging.
Point-of-Care Diagnostics for Rapid Infection Containment
Rapid point-of-care antigen screening enables immediate clinical decision-making, patient isolation, and treatment initiation at first point of healthcare contact across UAE clinics and hospitals.
Conserved Nucleoprotein Target
Detects the highly conserved structural nucleocapsid (N) protein of SARS-CoV-2 rather than the hypermutable spike protein, guaranteeing diagnostic fidelity across all current and evolving lineages.
- Omicron JN.1, KP.2 & KP.3 Lineage Detection
- No loss of sensitivity from spike mutations
- Calibrated for high viral load transmission risks
Immediate Bedside Action
Delivers conclusive visual readouts in 15 minutes, empowering clinicians to make on-the-spot triage decisions without waiting for central laboratory turnaround times.
- Emergency department acute screening
- Inpatient admission transmission control
- Occupational health & day surgery clearances
Zero Cold-Chain Logistics
Formulated for robust temperature stability up to 30°C, eliminating delicate refrigeration logistics and ensuring dependable performance across clinics in Dubai and the UAE.
- Room temperature storage (2°C – 30°C)
- 24-Month manufacturer shelf life
- Supplied complete with pre-dispensed buffer tubes
Multi-Center Clinical Evaluation (vs. RT-PCR Reference)
CE-IVD Validation Cohort (n = 620)| Diagnostic Parameter | Clinical Result | 95% Confidence Interval (CI) | Clinical Significance |
|---|---|---|---|
| Clinical Sensitivity | 97.10% | 93.8% – 98.9% | High positive agreement during acute symptomatic phase (Ct < 30) |
| Clinical Specificity | 99.50% | 98.4% – 99.9% | Extremely low false-positive rate prevents unnecessary patient quarantine |
| Overall Diagnostic Accuracy | 98.80% | 97.5% – 99.5% | Concordance across symptomatic and high-risk exposed cohorts |
| Limit of Detection (LoD) | 100 TCID50/mL | Analytical LoD Study | Reliably detects low-titer viral concentrations in nasal secretions |
| Cross-Reactivity | 0.0% Non-Reactive | Panel of 24 Pathogens | No cross-reactivity with Flu A, Flu B, RSV, Adenovirus, or MERS-CoV |
4-Step Standard Operating Procedure
Standardized clinical workflow requiring no specialized instrumentation or dedicated laboratory infrastructure.
Specimen Collection
Collect mucosal secretions via anterior nasal swab (insert 2–3 cm into both nostrils and rotate 5 times) or standard nasopharyngeal swab using the sterile flocked swab supplied.
Lysis & Extraction
Immerse the swab into the pre-filled extraction buffer tube. Rotate the swab head against the inner tube wall for 15 seconds while squeezing the flexible tube sides.
Sample Inoculation
Fit the dropper nozzle securely onto the tube. Invert vertically and dispense exactly 3 full drops of processed extract into sample well (S) of the cassette.
Result Readout
Observe the result window at exactly 15 minutes. Strong positives may appear within 3–5 minutes, but negative results must be confirmed at 15 minutes. Do not interpret past 20 minutes.
Visual Result Interpretation Guide
Clear lateral flow colorimetric bands provide unequivocal diagnostic answers in point-of-care settings.
Definitive Test Outcomes
Evaluation of bands formed across the reading zone:
Clinical Diagnostic Best Practices
Essential operational rules for healthcare staff:
Everything Required for Point-of-Care Testing
Supplied in self-contained clinical cartons of 25 tests, ready for immediate deployment without ancillary laboratory equipment.
Frequently Asked Questions
Need technical dossiers, batch release certificates, or wholesale pricing? Contact our clinical diagnostic team in Dubai.
Contact Clinical SpecialistDoes this test detect circulating Omicron variants and sublineages?
Yes. The assay specifically targets the conserved SARS-CoV-2 nucleocapsid (N) protein rather than the variable spike protein, ensuring consistent diagnostic sensitivity across all Omicron sublineages including BA.1, BA.5, XBB, JN.1, KP.2, and KP.3.
How quickly can results be reliably interpreted?
Results are definitively read at 15 minutes. Strongly positive samples with high viral load may display a distinct test line earlier (within 3 to 5 minutes), but negative results must be verified at the full 15-minute incubation period.
What clinical specimen types are validated for this test?
The assay is CE-IVD validated for human anterior nasal swabs and nasopharyngeal swabs collected using the supplied medical flocked swabs.
What is the analytical Limit of Detection (LoD)?
The calibrated analytical Limit of Detection is 100 TCID50/mL, providing superior sensitivity for detecting acute viral shedding during early symptom onset.
Is this kit intended for self-testing or clinical professional use?
This product is CE-IVD certified strictly for professional in vitro diagnostic use by trained healthcare personnel in hospitals, clinics, diagnostic centers, and point-of-care medical facilities.
Equip Your Clinic With QuRapid COVID-19 Rapid Antigen Tests
Order CE-IVD professional COVID-19 Antigen Rapid Test Kits with same-day dispatch across Dubai, Abu Dhabi, and the Northern Emirates. B2B bulk pricing available for clinics, hospitals, and corporate healthcare providers.